myasthenia gravis and other autoimmune disorders. That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab), which inhibit B cells across the board ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and challenges as it positions itself for long-term growth. Recent financial reports ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating yesterday.Invest with Confidence: ...

In a report released today, Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a price ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a complex landscape of opportunities and challenges as it positions itself ...

Structural derivatives of macrolide antibiotics, ketolides are erythromycin ... It also is contraindicated in patients with myasthenia gravis (Medical Economics, 2005). The most common side ...

Emerging evidence suggests that myasthenia gravis (MG) may also play a role in post-stroke fatigue ... treated with cholinergic drugs. Results: The study involved 96 participants with a mean age of 60 ...

In 2016, an international guidelines consensus paper from the Myasthenia Gravis Foundation of America-appointed Task ... a stressful period with less sleep, or they receive antibiotics or other ...

Background Myasthenia gravis is an autoimmune disorder of the neuromuscular ... Doses of immunosuppressive medications were able to be reduced in 12 of 14 patients but medications could be completely ...